Lung cancer remains the leading cause of cancer-related deaths.1 Early detection via screening and/or follow-up of incidental findings is critical because of the asymptomatic nature of lung cancer in its early stages. Without early detection, diagnosis and treatment are often at a late stage, resulting in much poorer outcomes.2 Making sure every patient who is identified with an incidental finding is followed up and making sure eligible patients are being screened are two ways that the gap can be closed today.
Without a systematic approach in place, manually managing such programs can be prohibitively time- and resource-intensive. Apart from screening, only 29% of incidental lung nodules receive appropriate follow-up.3
Philips can partner with you to support your program for early detection of lung cancer. Addressing these areas can help close gaps of inequities and find more lung cancer in early stages. We can help assess where you are today and build an approach to help expand the efficacy and reach of your screening program, as well as improve both the identification and follow-up of patients with incidental nodule findings.
Approximately 71% of all incidental lung nodules are not followed and managed appropriately3
Delays in lung cancer screening due to the COVID-19 pandemic are thought to have caused more than 95,000 additional deaths from lung cancer worldwide4
Actionable incidental lung nodules show a malignancy rate of 25%5
When diagnosed early and resected immediately, a lung cancer patient’s chance of survival in 10 years jumps to 92%6
CT screening reduces 10-year lung cancer mortality by 33% for women and 24% for men, compared to no screening7
Lung cancer screening remains vastly underused to date, with less than 20% of the high-risk, eligible population undergoing lung cancer screening. Low rates of lung cancer screening are even more noticeable among underserved populations.8
Philips can help by providing solutions to manage lung screenings and workflows for incidental pulmonary findings while fostering collaborative treatment decision-making. This means reliably keeping track of patients, including finding and following up with those who have incidental nodules.
Keep patients engaged with an immersive experience for patient comfort and ease during the scan. Excellence in CT imaging and in visualization and reporting of results adds to the success of your program.
The Philips Lung Cancer Orchestrator is an integrated lung cancer patient management system for both CT lung cancer screening programs and incidental pulmonary findings programs that monitors patients through various steps of their lung cancer screening and treatment decision journey. Enhancing confidence with automated tools, including operational analytics, the Lung Cancer Orchestrator helps identify and keep more patients – and streamline workflows. Providing a complete solution, the system also comes equipped with the multidisciplinary team facilitator to help coordinate collaborative clinical decision making.
DynaCAD Lung is a vendor neutral Computer-Aided Detection (CAD) system that provides a robust set of automated tools for radiologists to analyze multi-slice CT exams of the chest. With flexible report templates and automated image registration, DynaCAD Lung helps facilitate synchronous display and navigation of multiple patient exams for initial review and easy follow-up comparison of current and prior study findings.
Incisive CT helps you meet some of your organization’s most pressing challenges. Philips Incisive CT offers intellect at every step, from acquisition through results, and across all fronts: financial, clinical and operational. Like never before, operator and design efficiencies come together for wise decisions from start to finish with an unprecedented Tube for Life guarantee¹. Now with the CT Smart Workflow, Incisive CT has further differentiated itself. CT Smart Workflow is an entirely new package of AI enabled tools that bring you the industry’s fastest AI reconstruction, automatic patient positioning and so much more to aid successful exams with fast results at low dose. From motion-free cardiac imaging to interventional procedures with confidence, CT Smart workflow offers you advances that matter in your day-to-day imaging.
The Philips solution for lung cancer orchestration is in use at lung cancer screening programs such as at the Ohio State University Wexner Medical Center in the US, which detects approximately 10,000 lung nodules in a year.11
Philips CT solutions such as Incisive CT meet ACR guidelines for low-dose lung cancer screening and have advanced noise reduction to improve image quality so you can see what you need to see, when you need to see it.
If there’s anything that keeps me up at night, it’s ‘Are we missing anyone?’ I sleep better at night now knowing that we have a true system that reminds us and tracks those folks in their journey along the incidental nodule and lung screening pathway.”
Dr. Bill Mayfield
Chief Surgical Officer, Wellstar Health System
Philips can assess where you are today so you can build an approach to help you expand the reach of early detection of lung cancer in your community and offers innovative financing options tailored to your needs to help bring it all together. Discover how we can help you successfully orchestrate your lung cancer early detection program.
Philips IntelliSite Pathology Solution
The Philips IntelliSite Pathology Solution is for clinical pathology use, it is a digital pathology solution which is a highly scalable product with proven technology that enhances productivity with high-resolution digital images, collaborative features, and case management tools.
Philips Genomic Workspaces are binding your Pathology department to your Oncology department. From genomic annotation to molecular tumor boards, we cover your workflow. Now with exclusive access to MD Anderson's Precision Oncology Decision Support - connecting you to leading biomarker education and therapy recommendations.
We are always interested in engaging with you.
Let us know how we can help.
References 4 Alkatout I, et al. Has COVID-19 affected cancer screening programs? A systematic review. Front Oncol. 2021. 11:675038. doi: 10.3389/fonc.2021.675038
Results from case studies are not predictive of results in other cases. Results in other cases may vary.
1 International Agency for Research on Cancer, World Health Organization. Press Release N° 263. Latest global cancer data: Cancer burden rises to18.1 million new cases and 9.6 million cancer deaths in 2018. 12 September 2018.
2 Lane E, et al. Nearly twice as many people are now eligible for lung cancer screenings—here is what you need to know. Advisory Board publication. 2021.Washington, DC. www.advisory.com/sponsored/lung-cancer
3 Blagev DP, et al. Follow-up of incidental pulmonary nodules and the radiology report. J Am Coll Radiol. 2014;11:378-83. DOI: 10.1016/j.jacr.2013.08.003.
5 Tanner NT, et al. Management of pulmonary nodules by community pulmonologists: a multicenter observational study. Chest. 2015 Dec;148(6):1405-1414. doi: 10.1378/chest.15-0630. PMID: 26087071; PMCID: PMC4665735.
6 International Early Lung Cancer Action Program Investigators. Survival of patients with stage 1 lung cancer detected on CT screening. N Engl J Med. 2006;355:1763- 1771 DOI: 10.1056/NEJMoa060476.
7 Aberle DR, et al. The National Lung Screening Trial Research Team. Reduce lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. DOI: 10.1056/NEJMoa1102873.
8 Olazagasti C, et al. Let's Close the Gap: #ASCO21 Research Addresses Disparities in Lung Cancer Screening. ASCO Daily News. 2021. dailynews.ascopubs.org/do/10.1200/ADN.21.200659/full/
9 Statement from the American College of Radiology. July, 2020. www.acr.org/Media-Center/ACR-News-Releases/2020/Updated-USPSTF-Lung-Cancer-Screening-Guidelines-Would-Help-Save-Lives
10 Khorana A, et al. Increase in time to initiating cancer therapy and association with worsened survival in curative settings: A U.S. analysis of common solid tumors. J Clin Oncol. 2017;35(15_suppl): 6557-6557. DOI: 10.1200/JCO.2017.35.15_suppl.6557.
11 “New program aims to catch hundreds of early lung cancers.” wexnermedical.osu.edu/departments/innovations/pulmonology/new-lung-cancers-program
4 Alkatout I, et al. Has COVID-19 affected cancer screening programs? A systematic review. Front Oncol. 2021. 11:675038. doi: 10.3389/fonc.2021.675038
You are about to visit a Philips global content pageContinue
You are about to visit the Philips USA website.I understand
Vår webbplats visas bäst i senaste versionen av Microsoft Edge, Google Chrome eller Firefox.